009420.KS KSC
Hanall Biopharma Co., Ltd.
1W: -1.1%
1M: -16.3%
3M: -25.2%
YTD: -14.9%
1Y: +66.1%
3Y: +131.5%
5Y: +108.6%
₩46,100.00 ($34.34)
-2400.00 (-4.95%)
Weekly Expected Move ±7.7%
₩39018
₩42559
₩46100
₩49641
₩53182
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$2.3B
-125.0% ▼
Capital Expenditures
$948M
+95.9% ▲
5Y CAGR: -33.7%
Free Cash Flow
-$3.3B
+76.0% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$3.2B
+0.0% ▲
Net Change in Cash
$8.4B
+148.2% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $8.9B | $251M | $3.5B | -$1.8B | -$5.6B |
| Depreciation & Amort. | $2.7B | $3.1B | $3.2B | $3.1B | $3.6B |
| Stock-Based Comp. | $1.6B | $1.9B | $1.6B | $584M | $0 |
| Change in Working Capital | -$15.2B | $14.9B | $20.2B | $3.5B | -$9.5B |
| Other Non-Cash Items | -$695M | $5.2B | $1.1B | $3.9B | $9.1B |
| Operating Cash Flow | $840M | $25.2B | $29.6B | $9.4B | -$2.3B |
| — Investing Activities — | |||||
| Capital Expenditures | -$9.0B | -$7.7B | -$2.4B | -$1.6B | -$14.1B |
| Acquisitions (Net) | -$571M | $17M | -$1.0B | -$1.0B | $24M |
| Investment Purchases | $4.4B | -$2.9B | -$2.7B | -$3.1B | -$5.1B |
| Investment Sales | $17.5B | $548K | $0 | $4M | $0 |
| Other Investing | -$4.3B | $0 | -$5.8B | -$21.7B | $406M |
| Investing Cash Flow | $8.0B | -$10.6B | -$11.9B | -$27.5B | -$18.8B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$715M | -$699M | -$814M | -$942M | $30.9B |
| Stock Repurchased | $0 | -$10.0B | $0 | $0 | -$3.2B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | $0 | $0 | $0 | -$994M |
| Financing Cash Flow | -$307M | -$10.6B | -$814M | $760M | $29.6B |
| Net Change in Cash | $8.6B | $4.0B | $16.9B | -$17.3B | $8.4B |
| Cash End of Period | $12.8B | $16.8B | $33.7B | $16.4B | $24.7B |
| Free Cash Flow | -$8.2B | $17.5B | $20.4B | -$13.7B | -$3.3B |